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Background
Invasive fungal infections still have high morbidity and
mortality rates, especially in immunocompromised
patients, given the lack of specific symptomatology and of
fast and early diagnosis methods.
Methods
We present a retrospective study performed between
January 2011 – June 2014 in the National Institute of
Infectious Diseases “Prof. Dr. Matei Balş”, including
patients with invasive fungal infections and complete
clinical and biological data.
Results
18 patients met the inclusion criteria for the studied per-
iod, representing 40% of the patients with potentially inva-
sive fungal infections. The majority of patients were male,
and the average age was 44 years. Only 2 of the patients
apparently were not immunocompromised, the other 16
presenting HIV infection or fungal infections risk factors.
The fungal species identified were Cryptococcus neofor-
mans in 8 cases (40%) and Candida spp in 12 cases (60%),
out of which 75% consisted of non-albicans species. The
invasive fungi were isolated from blood cultures in 9 cases
(52.4%), cerebrospinal fluid in 8 cases (38.1%), tips of cen-
tral venous catheters in one case and from other patholo-
gical products in one case. The average period from
admission to identification was 9.6 days. The antifungal
susceptibility test indicated that 16 out of the 20 cases
(80%) were sensitive to fluconazole and only 20% were
dose-dependent sensitivity types. The patients were treated
mainly using monotherapy – 1 antifungal in 10 cases
(55%). Fluconazole was the most used agent, in 14 cases
(77.8%) followed by voriconazole in 7 cases and posacona-
zole in 4 cases. The average treatment duration was 37.7
days, the shortest being one day, and the longest 120 days.
6 out of 18 patients (33.3%) deceased: one patient present-
ing severe bacterial infection treated with prolonged anti-
biotherapy and 5 presenting C. neoformans meningitis
associated with HIV infection.
Conclusion
Although proper treatment was administered, the mor-
tality in invasive fungal infections remains high, given
the fact that they generally appear in already marred or
severely immunosuppressed patients.
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